The relationship between severe asthma eosinophilic phenotypes and the clinical response to benralizumab at 16 weeks

D. Jackson (London, United Kingdom), C. Roxas (London, United Kingdom), L. Green (London, United Kingdom), M. Fernandes (London, United Kingdom), L. Thompson (London, United Kingdom), J. Kavanagh (London, United Kingdom), G. D'Ancona (London, United Kingdom), A. Nanzer-Kelly (London, United Kingdom), B. Kent (London, United Kingdom)

Source: International Congress 2019 – Clinical studies of asthma treatments
Session: Clinical studies of asthma treatments
Session type: Thematic Poster
Number: 2547
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Jackson (London, United Kingdom), C. Roxas (London, United Kingdom), L. Green (London, United Kingdom), M. Fernandes (London, United Kingdom), L. Thompson (London, United Kingdom), J. Kavanagh (London, United Kingdom), G. D'Ancona (London, United Kingdom), A. Nanzer-Kelly (London, United Kingdom), B. Kent (London, United Kingdom). The relationship between severe asthma eosinophilic phenotypes and the clinical response to benralizumab at 16 weeks. 2547

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: